 |
PDBsum entry 1pxx
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
1pxx
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Oxidoreductase
|
 |
|
Title:
|
 |
Crystal structure of diclofenac bound to the cyclooxygenase active site of cox-2
|
|
Structure:
|
 |
Prostaglandin g/h synthase 2. Chain: a, b, c, d. Synonym: cyclooxygenase-2, cox-2, prostaglandin-endoperoxide synthase 2, prostaglandin h2 synthase 2, pgh synthase 2, pghs-2, phs ii, glucocorticoid-regulated inflammatory cyclooxygenase, gripghs, tis10 protein, macrophage activation-associated marker protein p71/73, pes- 2. Engineered: yes
|
|
Source:
|
 |
Mus musculus. House mouse. Organism_taxid: 10090. Gene: ptgs2 or cox2 or cox-2 or tis10 or pghs-b. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Expression_system_cell_line: sf9.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.90Å
|
R-factor:
|
0.254
|
R-free:
|
0.302
|
|
|
Authors:
|
 |
J.R.Kiefer,S.W.Rowlinson,J.J.Prusakiewicz,J.L.Pawlitz,K.R.Kozak, A.S.Kalgutkar,W.C.Stallings,L.J.Marnett,R.G.Kurumbail
|
Key ref:
|
 |
S.W.Rowlinson
et al.
(2003).
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.
J Biol Chem,
278,
45763-45769.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
07-Jul-03
|
Release date:
|
09-Sep-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q05769
(PGH2_MOUSE) -
Prostaglandin G/H synthase 2 from Mus musculus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
604 a.a.
552 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.14.99.1
- prostaglandin-endoperoxide synthase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
(5Z,8Z,11Z,14Z)-eicosatetraenoate + AH2 + 2 O2 = prostaglandin H2 + A + H2O
|
 |
 |
 |
 |
 |
(5Z,8Z,11Z,14Z)-eicosatetraenoate
|
+
|
AH2
|
+
|
2
×
O2
|
=
|
prostaglandin H2
|
+
|
|
+
|
H2O
Bound ligand (Het Group name = )
matches with 51.11% similarity
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
278:45763-45769
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.
|
|
S.W.Rowlinson,
J.R.Kiefer,
J.J.Prusakiewicz,
J.L.Pawlitz,
K.R.Kozak,
A.S.Kalgutkar,
W.C.Stallings,
R.G.Kurumbail,
L.J.Marnett.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
A variety of drugs inhibit the conversion of arachidonic acid to prostaglandin
G2 by the cyclooxygenase (COX) activity of prostaglandin endoperoxide synthases.
Several modes of inhibitor binding in the COX active site have been described
including ion pairing of carboxylic acid containing inhibitors with Arg-120 of
COX-1 and COX-2 and insertion of arylsulfonamides and sulfones into the COX-2
side pocket. Recent crystallographic evidence suggests that Tyr-385 and Ser-530
chelate polar or negatively charged groups in arachidonic acid and aspirin. We
tested the generality of this binding mode by analyzing the action of a series
of COX inhibitors against site-directed mutants of COX-2 bearing changes in
Arg-120, Tyr-355, Tyr-348, and Ser-530. Interestingly, diclofenac inhibition was
unaffected by the mutation of Arg-120 to alanine but was dramatically attenuated
by the S530A mutation. Determination of the crystal structure of a complex of
diclofenac with murine COX-2 demonstrates that diclofenac binds to COX-2 in an
inverted conformation with its carboxylate group hydrogen-bonded to Tyr-385 and
Ser-530. This finding represents the first experimental demonstration that the
carboxylate group of an acidic non-steroidal anti-inflammatory drug can bind to
a COX enzyme in an orientation that precludes the formation of a salt bridge
with Arg-120. Mutagenesis experiments suggest Ser-530 is also important in
time-dependent inhibition by nimesulide and piroxicam.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
FIG. 1. COX substrate binding modes. Stereo diagram of the
inhibitory binding mode of arachidonic acid to COX-2 (blue)
aligned with the productive binding mode, observed in COX-1
(beige). The substrate is nominally rotated 180° between the
two orientations, resulting in different coordination of the
carboxylic acid group. Amino acids shown are within van der
Waals contact of diclofenac except for Arg-120, Val-434, and
Arg-513, added for reference. Red text indicates the position of
the three amino acid differences between COX-1 and COX-2 within
the active site. The superposition was performed using amino
acids 113-122, 344-355, 385-391, and 522-532 and coordinate
Protein Data Bank files 1CVU [PDB]
and 1DIY [PDB]
. All molecular graphics were generated with Ribbons and
rendered with POV-Ray (36).
|
 |
Figure 6.
FIG. 6. Comparison of inhibitor binding to COX-2. a,
superposition of the structures of diclofenac (green) and
indomethacin (gold carbons; Protein Data Bank number 4COX [PDB]
) shows their differential coordination to the protein, despite
their comparable size and chemical composition. b, overlay of
the structures of diclofenac and the inhibitory mode of
arachidonic acid binding. Both ligands coordinate their acidic
groups with the side chains of Tyr-385 and Ser-530 despite their
dissimilar chemical structures.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2003,
278,
45763-45769)
copyright 2003.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.Parisini,
P.Metrangolo,
T.Pilati,
G.Resnati,
and
G.Terraneo
(2011).
Halogen bonding in halocarbon-protein complexes: a structural survey.
|
| |
Chem Soc Rev,
40,
2267-2278.
|
 |
|
|
|
|
 |
J.F.Standing,
D.Tibboel,
R.Korpela,
and
K.T.Olkkola
(2011).
Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1-12 years.
|
| |
Paediatr Anaesth,
21,
316-324.
|
 |
|
|
|
|
 |
V.Hähnke,
A.Klenner,
F.Rippmann,
and
G.Schneider
(2011).
Pharmacophore alignment search tool: influence of the third dimension on text-based similarity searching.
|
| |
J Comput Chem,
32,
1618-1634.
|
 |
|
|
|
|
 |
S.Alcaro,
A.Artese,
M.Botta,
A.T.Zizzari,
F.Orallo,
F.Ortuso,
S.Schenone,
C.Brullo,
and
M.Yáñez
(2010).
Hit identification and biological evaluation of anticancer pyrazolopyrimidines endowed with anti-inflammatory activity.
|
| |
ChemMedChem,
5,
1242-1246.
|
 |
|
|
|
|
 |
S.Bouaziz-Terrachet,
A.Toumi-Maouche,
B.Maouche,
and
S.Taïri-Kellou
(2010).
Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study.
|
| |
J Mol Model,
16,
1919-1929.
|
 |
|
|
|
|
 |
S.L.Regan,
J.L.Maggs,
T.G.Hammond,
C.Lambert,
D.P.Williams,
and
B.K.Park
(2010).
Acyl glucuronides: the good, the bad and the ugly.
|
| |
Biopharm Drug Dispos,
31,
367-395.
|
 |
|
|
|
|
 |
T.J.Gan
(2010).
Diclofenac: an update on its mechanism of action and safety profile.
|
| |
Curr Med Res Opin,
26,
1715-1731.
|
 |
|
|
|
|
 |
C.E.Rogge,
W.Liu,
R.J.Kulmacz,
and
A.L.Tsai
(2009).
Peroxide-induced radical formation at TYR385 and TYR504 in human PGHS-1.
|
| |
J Inorg Biochem,
103,
912-922.
|
 |
|
|
|
|
 |
D.Zhao,
X.Zhang,
Y.Guo,
W.Tan,
and
D.Lin
(2009).
Cyclooxygenase-2 Gly587Arg variant is associated with differential enzymatic activity and risk of esophageal squamous-cell carcinoma.
|
| |
Mol Carcinog,
48,
934-941.
|
 |
|
|
|
|
 |
G.Wu,
A.L.Tsai,
and
R.J.Kulmacz
(2009).
Cyclooxygenase competitive inhibitors alter tyrosyl radical dynamics in prostaglandin H synthase-2.
|
| |
Biochemistry,
48,
11902-11911.
|
 |
|
|
|
|
 |
P.Tosco,
and
L.Lazzarato
(2009).
Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin.
|
| |
ChemMedChem,
4,
939-945.
|
 |
|
|
|
|
 |
V.F.Roche
(2009).
A receptor-grounded approach to teaching nonsteroidal antiinflammatory drug chemistry and structure-activity relationships.
|
| |
Am J Pharm Educ,
73,
143.
|
 |
|
|
|
|
 |
V.Hähnke,
B.Hofmann,
T.Grgat,
E.Proschak,
D.Steinhilber,
and
G.Schneider
(2009).
PhAST: pharmacophore alignment search tool.
|
| |
J Comput Chem,
30,
761-771.
|
 |
|
|
|
|
 |
B.J.Anderson
(2008).
Paracetamol (Acetaminophen): mechanisms of action.
|
| |
Paediatr Anaesth,
18,
915-921.
|
 |
|
|
|
|
 |
J.F.Standing,
R.F.Howard,
A.Johnson,
I.Savage,
and
I.C.Wong
(2008).
Population pharmacokinetics of oral diclofenac for acute pain in children.
|
| |
Br J Clin Pharmacol,
66,
846-853.
|
 |
|
|
|
|
 |
L.W.Padgett,
A.C.Howlett,
and
J.Y.Shim
(2008).
Binding mode prediction of conformationally restricted anandamide analogs within the CB1 receptor.
|
| |
J Mol Signal,
3,
5.
|
 |
|
|
|
|
 |
A.M.Ali,
G.E.Saber,
N.M.Mahfouz,
M.A.El-Gendy,
A.A.Radwan,
and
M.A.Hamid
(2007).
Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors.
|
| |
Arch Pharm Res,
30,
1186-1204.
|
 |
|
|
|
|
 |
A.Peretz,
N.Degani-Katzav,
M.Talmon,
E.Danieli,
A.Gopin,
E.Malka,
R.Nachman,
A.Raz,
D.Shabat,
and
B.Attali
(2007).
A tale of switched functions: from cyclooxygenase inhibition to m-channel modulation in new diphenylamine derivatives.
|
| |
PLoS ONE,
2,
e1332.
|
 |
|
|
|
|
 |
F.Ahmed,
S.Adsule,
A.S.Ali,
S.Banerjee,
S.Ali,
S.Kulkarni,
S.Padhye,
and
F.H.Sarkar
(2007).
A novel copper complex of 3-benzoyl-alpha methyl benzene acetic acid with antitumor activity mediated via cyclooxygenase pathway.
|
| |
Int J Cancer,
120,
734-742.
|
 |
|
|
|
|
 |
V.Strand
(2007).
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
|
| |
Lancet,
370,
2138-2151.
|
 |
|
|
|
|
 |
W.Lim,
S.Lee,
I.Kim,
M.Chung,
M.Kim,
H.Lim,
J.Park,
O.Kim,
and
H.Choi
(2007).
The anti-inflammatory mechanism of 635 nm light-emitting-diode irradiation compared with existing COX inhibitors.
|
| |
Lasers Surg Med,
39,
614-621.
|
 |
|
|
|
|
 |
C.E.Rogge,
B.Ho,
W.Liu,
R.J.Kulmacz,
and
A.L.Tsai
(2006).
Role of Tyr348 in Tyr385 radical dynamics and cyclooxygenase inhibitor interactions in prostaglandin H synthase-2.
|
| |
Biochemistry,
45,
523-532.
|
 |
|
|
|
|
 |
N.Singh,
T.Jabeen,
S.Sharma,
R.K.Somvanshi,
S.Dey,
A.Srinivasan,
and
T.P.Singh
(2006).
Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7 A resolution.
|
| |
Acta Crystallogr D Biol Crystallogr,
62,
410-416.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Bingham,
P.J.Beswick,
D.E.Blum,
N.M.Gray,
and
I.P.Chessell
(2006).
The role of the cylooxygenase pathway in nociception and pain.
|
| |
Semin Cell Dev Biol,
17,
544-554.
|
 |
|
|
|
|
 |
C.Drahl,
B.F.Cravatt,
and
E.J.Sorensen
(2005).
Protein-reactive natural products.
|
| |
Angew Chem Int Ed Engl,
44,
5788-5809.
|
 |
|
|
|
|
 |
C.J.daCosta,
D.E.Kaiser,
and
J.E.Baenziger
(2005).
Role of glycosylation and membrane environment in nicotinic acetylcholine receptor stability.
|
| |
Biophys J,
88,
1755-1764.
|
 |
|
|
|
|
 |
R.G.Huff,
E.Bayram,
H.Tan,
S.T.Knutson,
M.H.Knaggs,
A.B.Richon,
P.Santago,
and
J.S.Fetrow
(2005).
Chemical and structural diversity in cyclooxygenase protein active sites.
|
| |
Chem Biodivers,
2,
1533-1552.
|
 |
|
|
|
|
 |
G.Ermondi,
G.Caron,
R.Lawrence,
and
D.Longo
(2004).
Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.
|
| |
J Comput Aided Mol Des,
18,
683-696.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |